Industry Focus

Alkermes’ ALKS-5461 gets a do-over, Celldex's lead drug is a bust, and the good and bad of Johnson & Johnson's Q1 earnings report. 

Thanks to Blooom for supporting Industry Focus. Get a month free with blooom401k.com/fool and code fool.

Direct download: 20180418_IF_Healthcare.mp3
Category:Podcast -- posted at: 3:30pm EST